221 related articles for article (PubMed ID: 21163528)
21. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
Chen R; Gandhi V; Plunkett W
Cancer Res; 2006 Nov; 66(22):10959-66. PubMed ID: 17108134
[TBL] [Abstract][Full Text] [Related]
22. Activity of the potent dual Abl/Src tyrosine kinase inhibitor FB2 against Bcr-Abl positive cell lines in vitro and in vivo.
Yuan X; Zhang Y; Zhang H; Jin J; Li X; Liu H; Feng Z; Chen X
Leuk Res; 2011 Feb; 35(2):237-42. PubMed ID: 20739063
[TBL] [Abstract][Full Text] [Related]
23. BCR/ABL mRNA targeting small interfering RNA effects on proliferation and apoptosis in chronic myeloid leukemia.
Zhu XS; Lin ZY; Du J; Cao GX; Liu G
Asian Pac J Cancer Prev; 2014; 15(12):4773-80. PubMed ID: 24998540
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
[TBL] [Abstract][Full Text] [Related]
25. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
[TBL] [Abstract][Full Text] [Related]
26. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
[TBL] [Abstract][Full Text] [Related]
27. Transcriptional activation of human LIM-HOX gene hLH-2 in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
Wu HK; Minden MD
Biochem Biophys Res Commun; 1997 May; 234(3):742-7. PubMed ID: 9175786
[TBL] [Abstract][Full Text] [Related]
28. Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity.
Xu R; Dong Q; Yu Y; Zhao X; Gan X; Wu D; Lu Q; Xu X; Yu XF
Leuk Res; 2006 Jan; 30(1):17-23. PubMed ID: 16023722
[TBL] [Abstract][Full Text] [Related]
29. Nuclear topography and expression of the BCR/ABL fusion gene and its protein level influenced by cell differentiation and RNA interference.
Bártová E; Harnicarová A; Pacherník J; Kozubek S
Leuk Res; 2005 Aug; 29(8):901-13. PubMed ID: 15978941
[TBL] [Abstract][Full Text] [Related]
30. Real-time quantitative reverse transcriptase polymerase chain reaction.
Fan H; Robetorye RS
Methods Mol Biol; 2010; 630():199-213. PubMed ID: 20300999
[TBL] [Abstract][Full Text] [Related]
31. NADPH oxidases as therapeutic targets in chronic myelogenous leukemia.
Sánchez-Sánchez B; Gutiérrez-Herrero S; López-Ruano G; Prieto-Bermejo R; Romo-González M; Llanillo M; Pandiella A; Guerrero C; Miguel JF; Sánchez-Guijo F; Del Cañizo C; Hernández-Hernández A
Clin Cancer Res; 2014 Aug; 20(15):4014-25. PubMed ID: 24833663
[TBL] [Abstract][Full Text] [Related]
32. Characterization of a monoclonal antibody specific for novel Bcr/Abl out-of-frame fusion proteins.
Casnici C; Volpe G; Crotta K; Panuzzo C; Lattuada D; Cabras CA; Longhi R; Saglio G; Marelli O
Hybridoma (Larchmt); 2011 Jun; 30(3):261-9. PubMed ID: 21707361
[TBL] [Abstract][Full Text] [Related]
33. WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene.
Montano G; Vidovic K; Palladino C; Cesaro E; Sodaro G; Quintarelli C; De Angelis B; Errichiello S; Pane F; Izzo P; Grosso M; Gullberg U; Costanzo P
Oncotarget; 2015 Sep; 6(29):28223-37. PubMed ID: 26320177
[TBL] [Abstract][Full Text] [Related]
34. The transcription factor IRF8 counteracts BCR-ABL to rescue dendritic cell development in chronic myelogenous leukemia.
Watanabe T; Hotta C; Koizumi S; Miyashita K; Nakabayashi J; Kurotaki D; Sato GR; Yamamoto M; Nakazawa M; Fujita H; Sakai R; Fujisawa S; Nishiyama A; Ikezawa Z; Aihara M; Ishigatsubo Y; Tamura T
Cancer Res; 2013 Nov; 73(22):6642-53. PubMed ID: 24242069
[TBL] [Abstract][Full Text] [Related]
35. ABL SH3 mutant inhibits BCR-ABL activity and increases imatinib sensitivity by targeting RIN1 protein in CML cell.
Liu X; Li Y; Wen L; Tao K; Xiao Q; Cao W; Huang Z; Gao M; Li H; Wang F; Feng W
Cancer Lett; 2015 Dec; 369(1):222-8. PubMed ID: 26321052
[TBL] [Abstract][Full Text] [Related]
36. 2',5'-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells.
Maran A; Waller CF; Paranjape JM; Li G; Xiao W; Zhang K; Kalaycio ME; Maitra RK; Lichtin AE; Brugger W; Torrence PF; Silverman RH
Blood; 1998 Dec; 92(11):4336-43. PubMed ID: 9834240
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop?
Lopotová T; Záčková M; Klamová H; Moravcová J
Leuk Res; 2011 Jul; 35(7):974-7. PubMed ID: 21511335
[TBL] [Abstract][Full Text] [Related]
38. BCR/ABL-mediated downregulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CCL19 and CCL21 in primary BCR/ABL-positive cells.
Jongen-Lavrencic M; Salesse S; Delwel R; Verfaillie CM
Leukemia; 2005 Mar; 19(3):373-80. PubMed ID: 15674360
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
[TBL] [Abstract][Full Text] [Related]
40. Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation.
Rangatia J; Bonnet D
Leukemia; 2006 Jan; 20(1):68-76. PubMed ID: 16281073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]